Physician profile
Aaron John Viray
NPI 1851683130
$2,125.11
in general payments reported to CMS, 2019-2025
25 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $122 · 2021: $204 · 2022: $205 · 2023: $136 · 2024: $406 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $419.51 | 2019-2025 | Trelegy Ellipta, Nucala |
| Intuitive Surgical, INC. | $192.66 | 2021-2024 | |
| Actelion Pharmaceuticals US, INC. | $159.39 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $125.80 | 2019-2022 | |
| Allergan, INC. | $123.75 | 2019 | |
| Ceribell, INC. | $114.92 | 2022 | |
| Inspire Medical Systems, INC. | $105.42 | 2024 | Inspire |
| Medtronic, INC. | $89.91 | 2024 | Illumisite |
| Ekos Corporation | $86.06 | 2019 | |
| Veran Medical Technologies, INC. | $75.62 | 2019 | |
| Genentech, INC. | $74.90 | 2019 | |
| Amgen INC. | $71.26 | 2025 | Tezspire, Tavneos |
| Pfizer INC. | $64.04 | 2019-2023 | |
| Genentech USA, INC. | $54.49 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $28.89 | 2023 | Jynarque |
| Advanced Respiratory, INC | $25.95 | 2019-2021 | |
| Baxter Healthcare | $25.17 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Tactile Systems Technology INC | $24.97 | 2025 | Nimbl, Flexitouch Plus |
| United Therapeutics Corporation | $24.27 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $24.14 | 2025 | Dupixent |
| Pulmonx Corporation | $19.13 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Amarin Pharma, INC. | $18.79 | 2020 | |
| Insmed, INC. | $16.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Viray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.